Sebastian Lundgren

ORCID: 0000-0001-5135-558X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Cancer Cells and Metastasis
  • Immunotherapy and Immune Responses
  • Neuroendocrine Tumor Research Advances
  • Immune Cell Function and Interaction
  • Gastrointestinal Tumor Research and Treatment
  • Renal cell carcinoma treatment
  • Estrogen and related hormone effects
  • Metastasis and carcinoma case studies
  • Bladder and Urothelial Cancer Treatments
  • Cutaneous Melanoma Detection and Management
  • Urinary and Genital Oncology Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Genetic factors in colorectal cancer
  • Cancer Treatment and Pharmacology
  • Pharmacogenetics and Drug Metabolism
  • Immune cells in cancer
  • Radiomics and Machine Learning in Medical Imaging
  • Veterinary medicine and infectious diseases
  • Artificial Intelligence in Games
  • Sex and Gender in Healthcare
  • Genetic Syndromes and Imprinting
  • Occupational and environmental lung diseases

The University of Texas MD Anderson Cancer Center
2023-2025

Lund University
2014-2022

Skåne University Hospital
2018

St Olav's University Hospital
2007-2017

Norwegian University of Science and Technology
2007

Helsinki University Hospital
1997

The critical role of the immune system in controlling cancer progression has become evident and modulatory therapy is now approved for clinical use. However, while majority studies on inflammatory tumour microenvironment have focused cellular response, particular prognostic predictive various T cell infiltrates, humoral response this context long been overlooked. This study aimed to investigate clinicopathological correlates impact B plasma infiltration epithelial ovarian (EOC)....

10.1186/s13048-016-0232-0 article EN cc-by Journal of Ovarian Research 2016-04-05

The development of a reactive tumour stroma is hallmark progression and pronounced generally considered to be associated with clinical aggressiveness. variability between types regarding fraction, its prognosis associations, have not been systematically analysed.Using an objective machine-learning method we quantified the in 16 solid cancer from 2732 patients, representing retrospective tissue collections surgically resected primary tumours. Image analysis performed segmentation into stromal...

10.1016/j.ebiom.2021.103269 article EN cc-by EBioMedicine 2021-03-01

Abstract Molecular routes to metastatic dissemination are critical determinants of aggressive cancers. Through in vivo CRISPR–Cas9 genome editing, we generated somatic mosaic genetically engineered models that faithfully recapitulate renal tumors. Disruption 9p21 locus is an evolutionary driver systemic disease through the rapid acquisition complex karyotypes cancer cells. Cross-species analysis revealed recurrent patterns copy number variations, including 21q loss and dysregulation...

10.1038/s43018-023-00584-1 article EN cc-by Nature Cancer 2023-06-26

Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic cancer, however, early clinical trials have been disappointing. The optimization of immunotherapeutic strategies requires better understanding the inflammatory tumor microenvironment. Therefore, aim our study was to perform a detailed in situ description lymphocyte infiltration patterns resected and other periampullary cancers. Multiplexed immunofluorescence imaging applied tissue microarrays with...

10.1002/ijc.32945 article EN cc-by International Journal of Cancer 2020-03-04

Dendritic cells (DC) and tumour-associated macrophages (TAM) are essential in linking the innate adaptive immune response against tumour progression. These also potential target for immunotherapy as well providing a handle to investigate status microenvironment. The aim of present study was examine their impact on prognosis chemotherapy periampullary adenocarcinoma, including pancreatic cancer, with particular reference morphological subtype. density tolerogenic immature CD1a+ dendritic...

10.1186/s12967-017-1256-y article EN cc-by Journal of Translational Medicine 2017-07-03

Background Natural killer (NK) cells and NK T (NKT) are vital parts of tumour immunosurveillance. However, their impact on prognosis chemotherapy response in periampullary adenocarcinoma, including pancreatic cancer, has not yet been described. Methods Immune cell-specific expression CD56, CD3, CD68 CD1a was analysed by immunohistochemistry tissue microarrays with tumours from 175 consecutive cases 110 pancreatobiliary type (PB-type) 65 intestinal (I-type) morphology. Kaplan-Meier Cox...

10.1371/journal.pone.0156497 article EN cc-by PLoS ONE 2016-06-08

High expression of the polymeric immunoglobulin receptor (PIGR) has previously been associated with a favourable prognosis in few cancer forms, but its and relationship clinical outcome epithelial ovarian (EOC) not yet reported. The aim this study was therefore to examine clinicopathological correlates prognostic significance PIGR EOC. After an initial screening Human Protein Atlas portal, validated antibody selected for extended analysis immunohistochemical tissue microarrays tumours from...

10.1186/1757-2215-7-26 article EN cc-by Journal of Ovarian Research 2014-02-26

Background: The clinical management of pancreatic and other periampullary neoplasms remains challenging. In contrast to cancer types, immunotherapies are largely ineffective, the reason for deprived immune response inhibiting cellular composition is only fragmentarily understood. aim this study was comprehensively map abundance, topographic distribution spatial interaction innate innate-like cells in tumour microenvironment adenocarcinoma. Methods: Multiplexed immunofluorescent imaging...

10.3389/fimmu.2020.558169 article EN cc-by Frontiers in Immunology 2020-09-10

There is a great unmet clinical need to identify patients with thin primary cutaneous melanomas (T1, Breslow thickness ≤ 1 mm) who have high risk for tumour recurrence and death from melanoma. Kin of IRRE-like protein (KIRREL/NEPH1) expressed in podocytes involved glomerular filtration. Screening the Human Protein Atlas portal revealed particularly expression KIRREL melanoma, both at mRNA levels. In this study, we followed up on these findings examined prognostic value population-based...

10.1186/s40364-018-0153-8 article EN cc-by Biomarker Research 2019-01-14

The Swedish variant of moist oral smokeless tobacco (snus) is popular in Sweden and Norway, banned from sale within the European Union currently being introduced USA. aim present study was to determine if snus carcinogenic stomach, particularly Helicobacter pylori ( H.P. )-infected hosts at increased risk for gastric cancer development. Snus (General™; Match, Sweden) mixed with powdered standard mouse chow a concentration 5–9% (wt/wt) given wild-type (WT, FVB) gastrin transgenic (INS-GAS,...

10.1093/carcin/bgm071 article EN Carcinogenesis 2007-03-27

Cartilage oligomeric matrix protein (COMP) is an emerging regulator of tumor progression. The aim this study was to evaluate the expression COMP in periampullary adenocarcinoma with respect prognostic value for survival and relapse, levels fibrosis infiltrating immune cells. evaluated using immunohistochemistry primary tumors subsets paired lymph node metastases tissue microarrays including 175 patients adenocarcinoma. Collagen content assessed Sirius Red-Fast Green staining. High were...

10.1080/2162402x.2022.2111906 article EN cc-by-nc OncoImmunology 2022-08-18

Periampullary adenocarcinomas encompass a heterogeneous group of tumors with dismal prognosis and limited treatment options. Emerging evidence shows that tumor morphology (ie, intestinal type [I-type] or pancreatobiliary [PB-type]) is more relevant prognostic factor than origin. Knowledge sparse, however, on whether key mutations differ according to morphology.Next-generation sequencing was applied assess the mutational status 70 genes in 102 from retrospective cohort 175 patients resected...

10.1200/po.18.00323 article EN cc-by JCO Precision Oncology 2019-03-21

Periampullary adenocarcinomas, including pancreatic cancer, are a heterogeneous group of tumors with poor prognosis, where classification into intestinal type (I-type) or pancreatobiliary (PB-type) is relevant prognostic factor. The clinical significance deficient mismatch repair (dMMR) in periampullary adenocarcinoma comparatively unexplored. Herein, we examined the associations MMR immunophenotype long-term survival patients resected adenocarcinoma, particular reference to morphology and...

10.1186/s12967-018-1444-4 article EN cc-by Journal of Translational Medicine 2018-03-14

Abstract Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role malignant progression, dissemination therapy response is controversial. More importantly, the of mesenchymal transition (EMT) cell tumor heterogeneity, clonal selection evolution poorly understood. Functionally, our work clarifies contribution EMT to progression metastasis pancreatic cancer. We leveraged ad hoc somatic mosaic genome engineering, lineage...

10.1101/2023.09.18.558231 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2023-09-19

Screening across a multitude of normal and malignant tissues revealed an enhanced expression lymphocyte antigen 6 superfamily member D (LY6D) in squamous epithelium urothelium, as well malignancies derived therefrom. The aim this study was to further delineate the protein LY6D urothelial bladder cancer, with particular attention its relationship clinicopathological characteristics patient outcome. Immunohistochemical assessed tissue microarrays cancer tumours from three independent cohorts;...

10.1186/s40364-020-00232-1 article EN cc-by Biomarker Research 2020-10-07

Abstract Renal medullary carcinoma (RMC) is a rare but highly aggressive SMARCB1-deficient kidney cancer that mainly afflicts young individuals of African descent and has few treatment options. Despite the advancements in immune checkpoint therapy (ICT) for other cancers, its efficacy against RMC remains elusive. The majority patients treated with ICT have experienced aggressively progressive disease as best response. This hyperprogression was confirmed our prospective clinical trial...

10.1158/1538-7445.am2024-2702 article EN Cancer Research 2024-03-22

267 Background: Adenocarcinomas in the pancreas and periampullary region are heterogenous with shared trait of having dismal prognosis. Despite recent progress cancer therapy this has not been reflected better prognosis for patient group. Research thus begun to explore role immune system pancreatic cancer. The aim study was analyze prognostic value CD56+ natural killer (NK) cells cancer, particular reference morphological type. Methods: Immunohistochemical expression CD56 lymphocytes tumor...

10.1200/jco.2016.34.4_suppl.267 article EN Journal of Clinical Oncology 2016-02-01

268 Background: Overall survival for patients with periampullary adenocarcinoma, including pancreatic cancer, continues to be poor. Pancreatic cancer is characterized by a largely immunosuppressive microenvironment, but blockade of the programmed death ligand 1 (PD-L1) pathway has still not been effective. Reports on prognostic value PD-L1 expression in and particular are sparse. The aim this study was therefore analyze specific reference morphological type, tumor-infiltrating immune cells,...

10.1200/jco.2018.36.4_suppl.268 article EN Journal of Clinical Oncology 2018-02-01

289 Background: Periampullary adenocarcinomas, including pancreatic cancer, are a heterogenous group of tumors with poor prognosis. Emerging evidence indicates that tumor morphology, i.e. intestinal type (I-type) or pancreatobiliary (PB-type), is more relevant prognostic factor than anatomical origin. The extent and clinical significance deficient mismatch repair (dMMR) in periampullary adenocarcinoma relatively unexplored. In this study, we examined the associations MMR status survival...

10.1200/jco.2018.36.4_suppl.289 article EN Journal of Clinical Oncology 2018-02-01
Coming Soon ...